Deniz Kirik
81 – 100 of 174
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease
(
- Contribution to journal › Article
-
Mark
A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System
(
- Contribution to journal › Article
-
Mark
Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates
(
- Contribution to journal › Article
-
Mark
Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain
(
- Contribution to journal › Article
-
Mark
Gene therapy for dopamine replacement.
(
- Contribution to journal › Scientific review
-
Mark
Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses.
(
- Contribution to journal › Article
-
Mark
Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease.
(
- Contribution to journal › Article
-
Mark
Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.
(
- Contribution to journal › Article
-
Mark
Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.
(
- Contribution to journal › Article
-
Mark
Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
(
- Contribution to journal › Article
-
Mark
Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease.
(
- Contribution to journal › Article
- 2009
-
Mark
Are the animal models of Parkinson's disease suitable for development of neuroprotective therapies?
2009) 4th European-Society-for-Neurochemistry Conference on Advances in Molecular Mechanisms of Neurological Disorders In Journal of Neurochemistry 110(Suppl 1). p.63-63(
- Contribution to journal › Published meeting abstract
-
Mark
Dose Optimization for Long-term rAAV-mediated RNA Interference in the Nigrostriatal Projection Neurons.
(
- Contribution to journal › Article
-
Mark
Differential Infectivity Following Basal Ganglia Administration of Differing AAV Serotypes in Nonhuman Primates
2009) 16th Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair In Cell Transplantation 18(2). p.212-213(
- Contribution to journal › Published meeting abstract
-
Mark
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT(1A) and 5-HT(1B) receptor agonists in the rat Parkinson model.
(
- Contribution to journal › Article
-
Mark
Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats
(
- Contribution to journal › Article
-
Mark
Proton NMR of (15)N-Choline Metabolites Enhanced by Dynamic Nuclear Polarization.
(
- Contribution to journal › Article
-
Mark
Suppression of Map Kinases Inhibits Microglial Activation and Attenuates Neuronal Cell Death Induced by Alpha-Synuclein Protofibrils
(
- Contribution to journal › Article
-
Mark
Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy
(
- Contribution to journal › Article
-
Mark
Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain.
(
- Contribution to journal › Article